July 1, 2019 09:35 AM EDTUpdated 10:24 AM
News Briefing

Up­dat­ed: Lon­za sets sights on ex­pan­sion, buy­ing No­var­tis fa­cil­i­ty; IQVIA leads $14 mil­lion Se­ries B fund­ing round

ENDPOINTS

→ Lon­za Phar­ma & Biotech is ex­pand­ing, buy­ing up a Swiss fa­cil­i­ty No­var­tis has been us­ing to pro­duce drug vials and plug­ging …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times